drugset / Trial / NCT01569035

Warfarine in Unexplained Oligohydramnios

NCT01569035

Phase 4 Terminated 200 enrolled Woman's Health University Hospital, Egypt
NaSingle-groupDouble-blindTreatment

Summary

This study examines using oral anti coagulant warfarin in the management of unexplained oligohydramnios improve the perinatal outcome with little or no complications to the mother or the neonates.

Timeline

Start
2009-01
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Warfarin Small molecule 3 mg Oral

Indications